Amneal二季度业绩超预期并上调全年指引，但股价盘初转跌

Microsoft surges on strong revenue outlook, maintained capex guidance
Introduction & Market Context
Amneal Pharmaceuticals (NYSE:AMRX) presented its second quarter 2026 earnings results on July 30, 2026, showcasing accelerating growth across its diversified portfolio and raising full-year guidance for the second consecutive quarter. The company reported revenue of $796 million, up 10% year-over-year, and adjusted EBITDA of $206 million, representing 12% growth. Despite beating analyst estimates, shares declined 3.25% to $18.48 from a previous close of $19.10, trading near the company’s 52-week high of $19.26 after a 137% run-up over the past year.
The presentation highlighted what CEO Chirag Patel described as "the most transformative period in our company’s history," with momentum building across specialty pharmaceuticals, complex generics, and an expanding biosimilars platform. This marks Amneal’s seventh consecutive year of revenue and earnings growth as the company executes on its strategy to shift from commodity generics toward higher-margin, differentiated medicines.
Quarterly Performance Highlights
As shown in the following summary of quarterly results, Amneal delivered broad-based growth across key financial metrics in the second quarter.
The company’s adjusted earnings per share of $0.30 represented a 20% increase from the prior year, exceeding Wall Street’s consensus estimate of $0.23 by 30.4%. Revenue of $796.2 million came in 5% above the $758.24 million forecast. Adjusted gross margin expanded 60 basis points to 46.2%, driven by favorable product mix and operating efficiencies.
For the first half of 2026, revenue reached $1.52 billion, up 7% year-over-year, while adjusted EBITDA grew 15.5% to $408 million. Adjusted EBITDA margins improved 200 basis points to 26.9%, reflecting the company’s successful shift toward more complex, higher-value products.
The following detailed breakdown illustrates the company’s second quarter financial performance across key metrics.
Operating cash flow turned negative at -$21 million in the quarter, compared to $84 million in the prior year period, reflecting higher inventory levels and timing of collections as the company prepared for upcoming product launches. Management maintained its full-year operating cash flow guidance of $350-400 million.
Segment Performance Analysis
Amneal’s three operating segments showed divergent trends in the quarter. The Affordable Medicines segment, which includes retail generics, injectables, and biosimilars, generated $490 million in revenue, up 13% year-over-year. This acceleration was driven by continued strength in complex products, particularly women’s health transdermal patches and injectable formulations, along with new ophthalmic product launches.
The Specialty segment posted $149 million in revenue, up 17% from the prior year, with first-half growth of 20% reaching $283 million. Growth was driven by all promoted brands, including CREXONT for Parkinson’s disease, the Brekiya autoinjector for migraine, UNITHROID for hypothyroidism, and EMVERM.
The AvKARE distribution segment reported $157 million in revenue, down 4% year-over-year, as the company focused on more profitable channels. Revenue from government contracts increased 12% to $147 million, while lower-margin distribution revenue declined 14%. Despite the revenue decline, gross margins improved 180 basis points to 20.2% for the first half.
Specialty Pharmaceuticals Momentum
The company’s specialty pharmaceuticals business is experiencing significant growth driven by two key branded products. As illustrated in the following chart, specialty segment revenue has grown from $356 million in 2020 to $529 million in 2025, representing an 8% compound annual growth rate.
CREXONT, approved for Parkinson’s disease, has been prescribed to more than 33,000 U.S. patients since launch and is on track to become the leading branded therapy in the Parkinson’s disease market. First-half 2026 revenue reached $50 million, up 147% from the prior year, with second quarter revenue of $29 million representing 157% growth.
The following detailed analysis shows CREXONT’s prescription growth trajectory and clinical performance advantages.
Monthly prescriptions have grown steadily from approximately 1,000 in October 2024 to more than 16,000 in June 2026. Phase 4 clinical data demonstrated substantial benefits versus other oral therapies, including 50% greater improvement in motor and non-motor scores compared to immediate-release carbidopa/levodopa and other competing products. Management expects U.S. peak sales of $300-500 million for CREXONT.
The Brekiya autoinjector for acute migraine treatment launched in the fourth quarter of 2025 and has generated $12 million in life-to-date revenue, ahead of expectations. As shown in the following market analysis, the product targets a large addressable market of patients who do not respond adequately to CGRP medications.
Quarterly revenue accelerated from $1.6 million in Q4 2025 to $5.5 million in Q2 2026. The company expects U.S. peak sales of $50-100 million, with potential for broad usage among patients experiencing severe, treatment-resistant headaches.
Affordable Medicines Transformation
Amneal’s Affordable Medicines segment is undergoing a strategic transformation toward more complex, differentiated products. As illustrated in the following revenue trend, the segment has grown from $1.34 billion in 2020 to $1.75 billion in 2025, with expectations for high single-digit growth in 2026.
The company is in the midst of what management described as "the most concentrated and impactful wave of high-value new launches in our company’s history." The following comprehensive table details the significant pipeline of recently approved and pending products.
Recent approvals include high-value products such as lenalidomide (Revlimid generic), rifaximin (Xifaxan generic), and denosumab biosimilars for osteoporosis and bone cancer. The company has also secured approvals for complex injectable products including romidepsin for oncology, iohexol contrast agent, and risperidone long-acting depot formulation.
Pending approvals include lanreotide injection, expected to launch in the third quarter of 2026, and an omalizumab biosimilar (Xolair) targeted for late fourth quarter 2026 or early 2027. Management noted that iohexol, a technically demanding sterile contrast agent essential for diagnostic imaging, could become a $50 million-plus opportunity over time given limited competition.
The portfolio mix is shifting meaningfully toward non-oral solid dosage forms, as shown in the following analysis.
Non-oral solid products, which include injectables, transdermals, ophthalmics, and inhalation products, now represent 59% of Affordable Medicines revenue, up from 35% in 2019. This shift supports higher margins and more durable competitive positioning. The company’s pipeline of approximately 66 programs represents roughly $48 billion in total addressable market, with 64% focused on complex products.
Biosimilar Strategy and Kashiv Acquisition
Amneal is positioning itself as a global biosimilar leader through organic development and the pending acquisition of Kashiv BioSciences. As detailed in the following strategic overview, the transaction is expected to close in the coming months pending shareholder approvals.
The acquisition provides Amneal with direct access to more than $300 billion in global biologic losses of exclusivity over the next decade, including $234 billion in the U.S. market. The Hart-Scott-Rodino waiting period expired in June 2026, and Indian regulatory approval has been received. Management expects the deal will have minimal impact on the company’s leverage profile, with a clear path to net leverage below 3x by 2028.
The combined biosimilar portfolio targets a market opportunity exceeding $100 billion, as illustrated in the following detailed pipeline breakdown.
Amneal expects to have six commercial biosimilars by 2027, including ALYMSYS (Avastin biosimilar), RELEUKO (Neupogen biosimilar), FYLNETRA (Neulasta biosimilar), BONCRESA (Prolia biosimilar), OZILTUS (XGEVA biosimilar), and an omalizumab biosimilar (Xolair). By 2030, the company anticipates having 12 or more commercial biosimilar products and more than 20 pipeline programs.
The portfolio includes a strategic mix of smaller molecules (less than $5 billion market size) and select large-market opportunities such as pembrolizumab (Keytruda, $19.5 billion market), dupilumab (Dupixent, $23.6 billion market), and risankizumab (Skyrizi, $28.4 billion market). This diversified approach aims to balance execution risk with significant market opportunity.
Long-Term Growth Trajectory
Amneal has demonstrated a consistent track record of growth and deleveraging since 2019. The following comprehensive analysis illustrates the company’s financial transformation and projections through 2030.
Net revenue has grown from $1.6 billion in 2019 to $3.02 billion in 2025, with expectations to reach $4.25-4.5 billion by 2030. Adjusted EBITDA has more than doubled from $339 million to $688 million over the same period, with 2030 targets of $1.15-1.25 billion. Operating cash flow has improved from just $2 million in 2019 to $340 million in 2025, with expectations for more than $700 million by 2030.
The company’s net leverage ratio has declined dramatically from 7.4x in 2019 to 3.5x at the end of 2025, and further to 3.6x as of the second quarter of 2026. Management expects to achieve net leverage below 3x by 2028, even after completing the Kashiv acquisition.
As shown in the following detailed revenue analysis by segment, growth has been driven by new product launches in Affordable Medicines and expansion of the Specialty portfolio.
Revenue from Affordable Medicines new launches has grown from $78 million in 2019 to $834 million in 2025, while Specialty revenue has expanded from $318 million to $529 million. The AVKARE distribution business has grown from $294 million in 2020 to $745 million in 2025, representing a 20% compound annual growth rate.
For the full year 2026, the company projects net revenue compound annual growth of 11% from 2019 to 2025, and adjusted EBITDA compound annual growth of 13% over the same period.
Strategic Initiatives and Partnerships
Beyond biosimilars, Amneal is investing in peptide manufacturing capabilities through its strategic collaboration with Pfizer to develop and manufacture GLP-1 therapies for obesity and metabolic disease. The global obesity and metabolic disease market is estimated at more than $150 billion by 2030.
Under the partnership, Amneal is constructing two new world-class manufacturing facilities for peptide synthesis and sterile fill-finish production. The company will serve as Pfizer’s preferred and majority supplier in the U.S., Europe, and other markets, while Amneal has been granted an exclusive license to commercialize products in 18 emerging markets, including India.
The company is also expanding its injectables portfolio with differentiated 505(b)(2) products that provide ready-to-use formulations of existing drugs. Recent launches include PEMRYDI RTU (pemetrexed for lung cancer), FOCINVEZ (fosaprepitant for chemotherapy-induced nausea), and BORUZU (bortezomib in a new presentation).
Financial Position and Updated Guidance
Amneal’s debt profile has improved significantly following a July 2026 refinancing that reduced the Term Loan B interest rate by 50 basis points from SOFR plus 300 basis points to SOFR plus 250 basis points. The blended cost of debt is now approximately 6%, down from roughly 10% in 2024, generating annual interest savings of about $12 million.
As of June 30, 2026, the company had gross debt of $2.78 billion and net debt of $2.66 billion, resulting in a net leverage ratio of 3.6x based on last twelve months adjusted EBITDA of $743 million.
The company raised its full-year 2026 guidance for the second consecutive quarter, as detailed in the following comparison.
Updated guidance calls for revenue of $3.1-3.2 billion (up from $3.05-3.15 billion previously), representing 3-6% growth over 2025. Adjusted EBITDA guidance increased to $750-780 million (from $740-770 million), implying 9-13% growth. Adjusted earnings per share guidance rose to $0.96-1.06 (from $0.95-1.05), representing 16-28% growth over 2025.
The updated outlook includes an estimated $20 million negative impact from flooding in Gujarat, India, where one of the company’s facilities was affected by severe rainfall. Capital expenditure guidance increased to approximately $150 million from $110 million previously, reflecting investments in women’s health patch capacity and U.S. sterile injectable manufacturing.
Management noted that Specialty segment growth is now expected to be high single digits in 2026, a significant improvement from previously flat expectations. The Affordable Medicines segment is also projected to deliver high single-digit growth, driven by new complex product launches and capacity expansion.
Looking further ahead, the company expects Affordable Medicines could add $1-2 billion in incremental revenue from 2026 through 2030, supported by capacity expansion, drug shortage-driven demand, and continued launches of complex generic products. Each of the company’s three segments is projected to deliver high single-digit long-term growth, with the Total Company expected to grow at a similar pace through the end of the decade.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.